Press Release

The full press release can be downloaded as a pdf.

ChromaCon AG obtains US patent for N-Rich Process

Zurich, January 2016. ChromaCon has been granted patent no. US 9,073,970 for ChromaCon's novel N-Rich^® process technology. The N-Rich^® process is a novel chromatographic process principle based on a twin-column configuration, offering significant advantages for the enrichment and purification of minor compounds amidst an excess of other compounds. The process principle is particularly suitable for isolation of product-related impurities, biosimilar isoforms and for the isolation of biomarkers and other proteomic applications. It is applied on the Contichrom^® CUBE equipment using the ChromIQ^® software. Once designed from a batch chromatogram using a user-friendly process wizard, the N-Rich^® process runs fully automatically, potentially saving weeks of work including tedious repetitive HPLC analytical separations and fraction analyses.

The process principle consists of the selective cyclic enrichment of target compounds that elute at a defined time-point and at the same time the depletion of overlapping non-target compounds. In this way, an enrichment of the target compound by hundred- or even thousand-fold can be achieved in an automated way overnight, saving weeks of tedious repetitive analytical injections.

To find out more about N-Rich^® and ChromaCon please contact us directly or visit our website www.chromacon.com

About ChromaCon

ChromaCon AG is a private Life Science Tool company located in Zürich, Switzerland, providing best-in-class process solutions to the biopharmaceutical industry. ChromaCon has developed and patented novel process principles, process control, equipment designs and operating software for batch, cyclic and continuous chromatography, providing significant CAPEX and OPEX cost savings and enabling scalable chromatographic solutions for large scale purification applications. The Contichrom® laboratory-scale equipment is co-marketed worldwide by ChromaCon and its partners. ChromaCon has provided global licenses for its process technologies to LEWA Process Technologies (Devens, MA, USA) for implementation into scale-up systems. ChromaCon also develops and markets affinity purification solutions for column and membrane chromatography applications and tools for site-specific protein conjugation.

ChromaCon Contact

To find out more about ChromaCon please contact us directly or visit our website.
Dr. Michael Bavand, CEO, info@chromacon.com, www.chromacon.com